Plain-English translation of NCT06168370 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study compares two approaches to preventing blood clots after you have had a catheter-based aortic valve replacement (TAVI). One group will receive lifelong aspirin as standard care. The other group will have a CT scan three months after the procedure to check for early blood clots on the new valve, and then receive apixaban (a blood thinner) only if clots are found. The goal is to reduce blood clots while lowering the risk of serious bleeding.
Currently, all patients after this valve procedure take aspirin for life to prevent blood clots, but this approach carries a bleeding risk without reliably stopping clots. This trial tests whether using CT imaging to personalize treatment—giving the medication only to patients who actually show signs of clotting—could work better and cause less harm.
You likely qualify if…
You likely don't qualify if…
If you join the study group, you will have a CT scan of your heart three months after your valve procedure. Based on the results, you may stop taking aspirin, or you may start taking apixaban if clots are detected. If you join the standard care group, you will continue taking aspirin for life as usual. You will be followed for about two years, with periodic visits to check how you are doing and watch for any blood clots or bleeding problems.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Netherlands